All News

Found 624,603 articles

• Astellas and Seattle Genetics Announce PADCEV® (enfortumab vedotin-ejfv) Significantly Improved Overall Survival in Phase 3 Trial in Previously Treated Locally Advanced or Metastatic Urothelial Cancer

  9/18/2020

  Astellas Pharma Inc. and Seattle Genetics, Inc. announced that a phase 3 trial of PADCEV® met its primary endpoint of overall survival compared to chemotherapy.

• Alkermes Presents New Clinical Data on ALKS 4230 in Mini Oral Presentation at 2020 European Society for Medical Oncology (ESMO) Virtual Congress

  9/18/2020

  Data Provide Evidence of Clinical Benefit and Tolerability of ALKS 4230 as Monotherapy in Melanoma and in Combination With Pembrolizumab in Multiple Tumor Types

• Pipeline Therapeutics Appoints Lori Lyons-Williams to its Board of Directors

  9/18/2020

  Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced the appointment of Lori Lyons-Williams to the company’s Board of Directors. Ms. Lyons-Williams brings more than 20 years of executive and operational experience to Pipeline. “I am thrilled that Lori will be joining the Pipeline board as an indepe

• Arena Pharmaceuticals to Present at the Jefferies Virtual Next Generation IBD Therapeutics Summit

  9/18/2020

  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi, the Company's President and Chief Executive Officer, will present a corporate update at the Jefferies Virtual Next Generation IBD Therapeutics Summit on Wednesday, September 23, at 1:45 PM ET. 

• Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo (nivolumab) Plus Yervoy (ipilimumab) Combined with Two Cycles of Chemotherapy as First-Line Treatment of Metastatic Non-Small Cell Lung Cancer

  9/18/2020

  Bristol Myers Squibb (NYSE: BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Opdivo® (nivolumab) plus Yervoy®

• Nemaura Medical Appoints Justin Mclarney as Chief Finance Officer

  9/18/2020

  Nemaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announces it has appointed Justin Mclarney as Chief Finance Officer, effective September 15, 2020. Dr. Faz Chowdhury, Nemaura Medical’s Chief Executive Officer commented,

• Generex Signs Binding Licensing & Research Agreement with Bintai Kinden to Advance the Clinical Development & Commercialization of Ii-Key-SARS-CoV-2 Coronavirus Vaccine for Malaysia

  9/18/2020

  Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce that the company and Bintai Kinden Corporation of Malaysia have signed an addendum binding the terms of the previously signed Memorandum of Understanding for the development and commercialization of the Ii-Key-SARS-CoV-2 coronavirus vaccine.

• SpringWorks Therapeutics Enters into Sponsored Research Agreement with Fred Hutchinson Cancer Research Center to Further Evaluate Nirogacestat as a BCMA Potentiator in Multiple Myeloma

  9/18/2020

  SpringWorks Therapeutics, Inc. announced that it has entered into a sponsored research agreement with Fred Hutchinson Cancer Research Center to further explore the ability of SpringWorks’ investigational gamma secretase inhibitor, nirogacestat, to modulate B-cell maturation antigen and potentiate BCMA-targeting therapies, including radioimmunotherapies, in a variety of preclinical and patient-derived multiple myeloma models developed by researchers at Fred Hutch.

• Autolus Therapeutics presents additional data on AUTO3 in DLBCL during the ESMO Virtual Congress 2020

  9/18/2020

  Autolus Therapeutics plc announced new data highlighting progress on AUTO3, the company’s CAR T cell therapy being investigated in the ALEXANDER study, a Phase 1/2 clinical trial in relapsed/refractory diffuse large B cell lymphoma, during the European Society for Medical Oncology Virtual Congress 2020, beginning 18 September.

• Agenus Presents Results from Two Large Cervical Cancer Trials at ESMO

  9/18/2020

  160 patient balstilimab (PD-1) monotherapy trial achieves response rates of 14% in all treated patients and 19% in PD-L1 positive patients

• Vifor Pharma Group Announces Successful Sale of OM Pharma

  9/18/2020

  Vifor Pharma has announced the successful sale of 100% of the share capital of OM Pharma, a Vifor Pharma Group company to Optimus Holding Ltd.

• ESMO 2020: Phase II CLARINET FORTE Results Show Increasing Dose Frequencies of Somatuline® Autogel® (lanreotide) Allows Patients with NETs to Delay Treatment Escalation by up to 8.3 Months

  9/18/2020

  Increasing the dose frequency of lanreotidefrom monthly to bi-monthly achieved a progression-free survival of 8.3 months in patients with progressive midgut neuroendocrine tumors (NETs) and 5.6 months in patients with progressive pancreatic NETs

• Incyte Announces Encouraging Results From Phase 2 Trial of Retifanlimab (INCMGA0012) in Patients With Previously Treated, Advanced Squamous Cell Carcinoma of the Anal Canal

  9/18/2020

  Independent central review confirmed responses include 1 complete response, 12 partial responses and 33 stable disease for an objective response rate of 14% and disease control rate of 49%

• Beech Tree Labs selects Curavit Clinical Research for fully virtual COVID-19 clinical trial

  9/18/2020

  Beechtree Labs has chosen Curavit Clinical Research for a fully decentralized clinical trial to investigate a promising Covid-19 therapy.

• Positive Pivotal Data for Libtayo® (cemiplimab) Monotherapy in Locally Advanced Basal Cell Carcinoma Featured as a Late-breaking Presentation at ESMO

  9/18/2020

  Regeneron Pharmaceuticals, Inc. and Sanofi announced the presentation of positive results from the pivotal Phase 2 trial for the PD-1 inhibitor Libtayo® in patients with locally advanced basal cell carcinoma who had progressed on or were intolerant to hedgehog inhibitor therapy.

• Daiichi Sankyo Announces Late-Breaking Phase 1 Dose Expansion Data for Patritumab Deruxtecan in Patients with EGFR-Mutated NSCLC at ESMO 2020

  9/18/2020

  HER3 directed ADC demonstrates clinical activity in patients with EGFR-mutated metastatic or unresectable NSCLC previously treated with a tyrosine kinase inhibitor and platinum-based chemotherapy in first presentation of dose expansion data for patritumab deruxtecan

• BAVENCIO Pivotal Phase III JAVELIN Bladder 100 Results Published in The New England Journal of Medicine

  9/18/2020

  EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. announced the publication of detailed results from the Phase III JAVELIN Bladder 100 study online ahead of print in The New England Journal of Medicine.

• Hyundai Hope On Wheels To Host Virtual 'Celebration Of Hope Awards' On Saturday, September 19 At 4 P.M. EDT

  9/18/2020

  - Annual event honoring National Childhood Cancer Awareness Month brings together Hyundai executives and dealers, congressional leaders, child cancer survivors, and doctor-researchers, to raise awareness and spread hope for pediatric cancer - Hyundai announces grant awards totaling $6.8 million dollars to help eradicate the disease   [18-September-2020]   FOUNTA

• Appili Therapeutics Virtually Opens The Market

  9/18/2020

  Dr. Armand Balboni , CEO, Appili Therapeutics Inc. (TSX: APLI), joined his team and Sophie Van Houtte , Head, Company Services, TMX Group, to celebrate the company's graduation from TSX Venture Exchange to Toronto Stock Exchange and open the market.  Appili Therapeutics Inc. was founded to advance the global fight against infectious d

• 3D Laparoscopy Market: Increasing usage of the laparoscopic technique worldwide is anticipated to boost the market

  9/18/2020

  Laparoscopy is a diagnostic procedure used to observe the abdominal section of a body.